Cost containment policies - can the industry survive? Steve Winter Newsletter Article 16 February 2013 Pages: 3 - 4
Look beyond price - consider all costs associated with depression Newsletter Article 16 February 2013 Pages: 5 - 5
Alglucerase - a ‘paradigm’ of innovative drug therapy? Newsletter Article 16 February 2013 Pages: 7 - 7
News from the European Symposium on Pharmacoeconomics Newsletter Article 16 February 2013 Pages: 8 - 9
Cost education effective for optimising parenteral drug use Newsletter Article 16 February 2013 Pages: 9 - 9
SSRI prescribing unwarranted for suicide prevention Newsletter Article 16 February 2013 Pages: 10 - 10
Cost-effective strategies for managing acid-related diseases Newsletter Article 16 February 2013 Pages: 10 - 11
No cost savings with epoetin for premature neonates Newsletter Article 16 February 2013 Pages: 11 - 11
Moclobemide favoured over fluoxetine for depression? Newsletter Article 16 February 2013 Pages: 11 - 12
How to conduct a ‘careful’ cost analysis for migraine Newsletter Article 16 February 2013 Pages: 12 - 13